Strategies for improving outcomes for gastric cancer

Journal of Gastroenterology and Hepatology (Australia)

Volumn 22, Issue 7, 2007, Pages 965-967

  Chiba, Tsutomu ^a   Aoi, Takashi ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; CANCER STAGING; CARCINOGENESIS; CHROMOENDOSCOPY; EDITORIAL; ENDOSCOPY; ETHNICITY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HIGH RISK POPULATION; HUMAN; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; STOMACH SURGERY;

EID: 34347392172     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2007.04996.x     Document Type: Editorial

References (24)

1. Ministry of Health and Welfare, Japan. Statistics of Cancer in Japan. Tokyo : Ministry of Health and Welfare, Japan, 2001.
2. The Japan Canceer Surveillance Research Group. Cancer incidence and incidence rates in Japan in 2000: estimates based on data from 11 population-based cancer registries. Jpn. J. Clin. Oncol. 2006 36 : 668 75.
3. Yeoh K-G. How do we improve outcomes for gastric cancer? J. Gastroenterol. Hepatol. 2007 22 : 970 2.
4. Chiba T, Seno H, Marusawa H, Wakatsuki Y, Okazaki K. Host factors are important in determining clinical outcomes of Helicobacter pylori infection. J. Gastroenterol. 2006 41 : 1 9.
5. Parkin DM, Whelan SL, Ferlay J et al., eds. Cancer Incidence in Five Continents, Vol. VIII. IARC Scientific Publication no. 155. Lyon : IARC Scientific Publications, 2002.
6. Goh KL, Cheah PL, Quek KF, Parasakthi N. Ethnicity and H. pylori as risk factors for gastric cancer in Malaysia: a prospective case control study. Am. J. Gastroenterol. 2007 102 : 40 5.
7. Ohata H, Kitauchi S, Yoshimura N et al. Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int. J. Cancer 2004 109 : 138 43.
8. El-Omar EM, Carrington M, Chow WH et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000 404 : 398 402.
9. Machado JC, Figueiredo C, Canedo P et al. A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology 2003 125 : 364 71.
10. Seno H, Satoh K, Tsuji S et al. Novel interleukin-4 and interleukin-1 receptor antagonist gene variations associated with non-cardia gastric cancer in Japan: Comprehensive analysis of 207 polymorphisms of 11 cytokine genes. J. Gastroenterol. Hepatol. 2007 22 : 729 37.
11. Yang J, Hu Z, Xu Y et al. Interleukin-1β gene promoter variants are associated with an increased risk of gastric cancer in a Chinese population. Cancer Lett. 2004 215 : 191 8.
12. Chang YW, Jang JY, Kim NH et al. Interleukin-β (IL-1β) polymorphisms and gastric mucosal levels of IL-1β cytokine in Korean patients with gastric cancer. Int. J. Cancer 2005 114 : 465 71.
13. Aoi T, Marusawa H, Sato T, Chiba T, Maruyama M. Risk of subsequent development of gastric cancer in patients with previous gastric epithelial neoplasia. Gut 2006 55 : 588 9.
14. Uemura N, Mukai T, Okamoto S et al. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol. Biomarkers Prev. 1997 6 : 639 42.
15. Nakagawa S, Asaka M, Kato M et al. Helicobacter pylori eradication and metachronous gastric cancer after endoscopic mucosal resection of early gastric cancer. Aliment. Pharmacol. Ther. 2006 24 (Suppl. 4 214 18.
16. Wong BCY, Lam SK, Wong WM et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China - a randomized controlled trial. JAMA 2004 291 : 187 94.
17. Ichikawa W, Takahashi T, Suto K et al. Simple combinations of 5-FU pathway genes predict the outcome of metastatic gastric cancer patients treated by S-1. Int. J. Cancer 2006 119 : 1927 33.
18. Mimori K, Sadanaga N, Yoshikawa Y et al. Reduced tau expression in gastric cancer can identify candidates for successful Paclitaxel treatment. Br. J. Cancer 2006 94 : 1894 7.
19. Ruzzo A, Graziano F, Kawakami K et al. Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. J. Clin. Oncol. 2006 24 : 1883 91.
20. Yoshimura A, Sugihara H, Ling ZQ et al. How wild-type TP53 is inactivated in undifferentiated-type gastric carcinomas: analyses of intratumoral heterogeneity in deletion and mutationof TP53. Pathobiology 2006 73 : 40 9.
21. Losi L, Baisse B, Bouzourene H et al. Evolution of intratumoral genetic heterogeneity during colorectal cancer progression. Carcinogenesis 2005 26 : 916 22.
22. Reya T, Morrison SJ, Clarke MF et al. Stem cells, cancer, and cancer stem cells. Nature 2001 414 : 105 11.
23. Maekita T, Nakazawa K, Mihara M et al. High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosa and its possible association with gastric cancer risk. Clin. Cancer Res. 2006 12 : 989 95.
24. Matsumoto Y, Marusawa H, Kinoshita K et al. Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium. Nat. Med. 2007 13 : 470 476.